今日の臨床サポート 今日の臨床サポート
関連論文:
img  12:  A clinical trial of amygdalin (Laetrile) in the treatment of human cancer.
 
著者: C G Moertel, T R Fleming, J Rubin, L K Kvols, G Sarna, R Koch, V E Currie, C W Young, S E Jones, J P Davignon
雑誌名: N Engl J Med. 1982 Jan 28;306(4):201-6. doi: 10.1056/NEJM198201283060403.
Abstract/Text One hundred seventy-eight patients with cancer were treated with amygdalin (Laetrile) plus a "metabolic therapy" program consisting of diet, enzymes, and vitamins. The great majority of these patients were in good general condition before treatment. None was totally disabled or in preterminal condition. One third had not received any previous chemotherapy. The pharmaceutical preparations of amygdalin, the dosage, and the schedule were representative of past and present Laetrile practice. No substantive benefit was observed in terms of cure, improvement or stabilization of cancer, improvement of symptoms related to cancer, or extension of life span. The hazards of amygdalin therapy were evidenced in several patients by symptoms of cyanide toxicity or by blood cyanide levels approaching the lethal range. Patients exposed to this agent should be instructed about the danger of cyanide poisoning, and their blood cyanide levels should be carefully monitored. Amygdalin (Laetrile) is a toxic drug that is not effective as a cancer treatment.

PMID 7033783  N Engl J Med. 1982 Jan 28;306(4):201-6. doi: 10.1056/NEJM198201283060403.
戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから